US5059611A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-inflammatory 5-hydroxy-2-furanones
Assignee: Allergan Inc
•
Filing: 1989-10-25
•
Granted: 1991-10-22
•
Expires: 2009-10-25
Abstract
Abstract New 5-hydroxy-2-furanone compounds have anti-inflammatory, immunosuppressive and anti-proliferative activity and are useful in treating psoriasis and modifying calcium homeostasis.
Inventors
- 👤 Gary C. M. Lee
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 12:58
CPC Classifications
C; C07; C07F; C07F7/00; C07F7/02; C07F7/08; C07F7/0803; C07F7/081; C07F7/0812; C07F7/0814; A; A61; A61P; A61P29/00; A61P37/00; A61P37/08; C07D; C07D307/00; C07D307/02; C07D307/34; C07D307/56; C07D307/60; C07F9/00; C07F9/02; C07F9/547; C07F9/655; C07F9/65515
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
172 words
A compound of the formula: ##STR7## in which A is ##STR8## n is 1 or 2; q is 1-4; m is 8-12; R is C 7 -C 14 alkyl, C 7 -C 14 alkoxide, NR 3 (CH 2 ) p Z or C.tbd.CM; p is 2-8; Z is H, N(R 3 ) 2 or CO 2 H; R 1 is hydrogen or C 1 -C 4 alkyl; R 2 is C 7 -C 14 alkyl or phenyl; M is C 7 -C 14 alkyl; phenyl(C 1 -C 4 alkyl) optionally substituted on the phenyl ring by 1-3 halo substituents; pyridyl(C 1 -C 4 alkyl) or naphthyl(C 1 -C 6 alkyl); R 4 is O--(C 8 -C 14 alkyl) or NH(C 8 -C 14 alkyl); and R 5 is hydrogen or R 4 is OH and R 5 is o-hydroxyphenyl; X is hydrogen, acetyl, PO(OH) 2 or CO(CH 2 ) 3 N(R 32 ).HCl; R 3 is C 1 -C 4 alkyl and R 6 is phenyl or C 4 -C 12 alkyl.
Claim 2
Dependent Claim
172 words
A compound of the formula: ##STR7## in which A is ##STR8## n is 1 or 2; q is 1-4; m is 8-12; R is C 7 -C 14 alkyl, C 7 -C 14 alkoxide, NR 3 (CH 2 ) p Z or C.tbd.CM; p is 2-8; Z is H, N(R 3 ) 2 or CO 2 H; R 1 is hydrogen or C 1 -C 4 alkyl; R 2 is C 7 -C 14 alkyl or phenyl; M is C 7 -C 14 alkyl; phenyl(C 1 -C 4 alkyl) optionally substituted on the phenyl ring by 1-3 halo substituents; pyridyl(C 1 -C 4 alkyl) or naphthyl(C 1 -C 6 alkyl); R 4 is O--(C 8 -C 14 alkyl) or NH(C 8 -C 14 alkyl); and R 5 is hydrogen or R 4 is OH and R 5 is o-hydroxyphenyl; X is hydrogen, acetyl, PO(OH) 2 or CO(CH 2 ) 3 N(R 32 ).HCl; R 3 is C 1 -C 4 alkyl and R 6 is phenyl or C 4 -C 12 alkyl.
Claim 3
Dependent Claim
50 words
A compound of claim 1 in which A is CH 2 CO 2 M, CH 2 CH 2 OCOR, (CH 2 ) n CH═CHCOR, (CH 2 ) q COR, ##STR9## (CH 2 ) m OX, (CH 2 ) m CO 2 R 1 , CH 2 C.tbd.CCOR 2 or ##STR10##
Claim 4
Dependent Claim
26 words
A compound of claim 1 in which A is CH 2 CO 2 M, CH 2 CH 2 OCOR, (CH 2 ) n CH═CHCOR or ##STR11##
Claim 5
Dependent Claim
12 words
A compound of claim 3 in which A is CH 2 CH═CHCOR.
Claim 6
Dependent Claim
5 words
The compound which is 4-(5-oxo-3-hexadecenyl)-5-hydroxy-2(5H)-furanone.
Claim 7
Dependent Claim
5 words
The compound which is 4-(5-oxo-3-hexadecenyl)-5-hydroxy-2(5H)-furanone.
Claim 8
Dependent Claim
5 words
The compound which is 4-(3-dodecanoyloxypropyl)-5-hydroxy-2(5H)-furanone.
Claim 9
Dependent Claim
5 words
The compound which is 4-(3-dodecanoyloxypropyl)-5-hydroxy-2(5H)-furanone.
Claim 10
Dependent Claim
5 words
The compound which is 4-(2-carbomethoxytridecyl)-5-hydroxy-2(5H)-furanone.
Claim 11
Dependent Claim
5 words
The compound which is 4-(2-carbomethoxytridecyl)-5-hydroxy-2(5H)-furanone.
Claim 12
Dependent Claim
5 words
The compound which is 4-(2-carbooctanoxy)ethyl-5-hydroxy-2(5H)-furanone.
Claim 13
Dependent Claim
5 words
The compound which is 4-(2-carbooctanoxy)ethyl-5-hydroxy-2(5H)-furanone.
Claim 14
Dependent Claim
20 words
A anti-flammatory pharmaceutical composition which comprises a pharmaceutical carrier and a therapeutically effective amount of a compound of claim 1.
Claim 15
Dependent Claim
37 words
A method of treating inflammation or an allergic response in a mammal which comprises administering to a mammal a therapeutically effective amount of a compound of claim 1 alone or in conjunction with a pharmaceutically acceptable excipient.
Claim 16
Dependent Claim
31 words
A method of treating psoriasis which comprises administering to a mammal a therapeutically effective amount of a compound of claim 1 either alone or in conjunction with a pharmaceutically acceptable excipient.
References Cited (Backward Citations)
US2359208A
Cited
US2359096A
Cited
US4447455A
Cited
EP0133376A1
Cited
US4789749A
Cited
EP0209274A2
Cited
US4786651A
Cited
US4855320A
Cited
EP0295056A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-10-21 | 1995-04-22 | 1995-10-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-10-21 | 1999-04-22 | 1999-10-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-10-21 | 2003-04-22 | 2003-10-22 | $7700.00 | Window Closed / Lapsed |